Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients

References

• Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med. 2005;352:1163.
   Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple Myeloma. Med Sci (Basel). 2021;9(1):3.
   PubMedGoogle Scholar
• National Cancer Institute Surveillance, Epidemiology, and End Results Program. Myeloma—Cancer Stat Facts. [cited 2020 Sep 25]. Available online: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063–6073.
   PubMed Web of Science ®Google Scholar
• Bal S, Giri S, Godby KN, et al. New regimens and directions in the management of newly diagnosed multiple myeloma. Am J Hematol. 2021;96(3):367–378.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Langseth ØO, Myklebust TÅ, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol. 2020 ;191(3):418–425.
   PubMed Web of Science ®Google Scholar
• Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–233.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–2074.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple Myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910.
   PubMed Web of Science ®Google Scholar
• Bonello F, Boccadoro M, Larocca A. Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients. Cancers (Basel). 2020;12(11):3106.
   Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet. 2007;370(9594):1209–1218.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, openlabel, phase 3 trial. Lancet. 2017;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–1330.
   PubMed Web of Science ®Google Scholar
• Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. Blood. 2021;137(26):3616–3628.
   Web of Science ®Google Scholar
• Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as post-induction maintenance for patients with newly diagnosed multiple Myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030–4041.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–141.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525–4530.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Das DS, Ray A, Song Y, et al. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD ® immunomodulatory drug pomalidomide. Br J Haematol. 2015;171(5):798–812.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 1;31(4):448–455.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101–5109.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomized trial. Lancet Oncol. 2010;11:934–941.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301–310.
   PubMed Web of Science ®Google Scholar
• Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027–3036.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Martínez-López J, Hernández MT, et al. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood. 2016;127(4):420–425.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.
   PubMed Web of Science ®Google Scholar
• O’Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222–230.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734.
   PubMed Web of Science ®Google Scholar
• Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953–1963.
   PubMed Web of Science ®Google Scholar
• Gay F, Cerrato C, Petrucci MT, et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial. J Clin Oncol. 2019;37(15_suppl):8002.
   Web of Science ®Google Scholar
• Gay F MD, Musto P, Rota SD, et al. Survival analysis of newly diagnosed transplant-eligible multiple Myeloma patients in the randomized forte trial. Blood. 2020;136(Suppl 1):35-37.
   Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5321.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Paiva B, Sáenz de Tejada IM, Dimopoulos MA, et al. Measurable residual disease (MRD) evaluation during ixazomib (ixa) maintenance in newly diagnosed multiple myeloma (NDMM): a large analysis of 1280 patients (pts) enrolled in TOURMALINE-MM3 and -MM4. HemaSphere. 2021;5(S2):47-48.
   Google Scholar
• van de Donk NWCJ, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6):681–695.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for multiple Myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for multiple Myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for relapsed or refractory multiple Myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity with daratumumab in newly diagnosed multiple Myeloma: MAIA and ALCYONE. Blood. 2021 Jul 16; online ahead of print. DOI:https://doi.org/10.1182/blood.2020010439.
   Google Scholar
• Kumar SK, Facon T, Usmani SZ, et al. Updated analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in patients with transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): the phase 3 Maia Study. Blood. 2020;136(Suppl 1):24-26.
   Google Scholar
• Facon T, Kumar S, Plesner T, et al. Overall survival results with daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at European Hematology Association Annual Meeting. 2021;Virtual Abstract LB1901.
   Google Scholar
• Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486–1494.
   PubMed Web of Science ®Google Scholar
• Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, Daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple Myeloma: the Hovon 143 study. J Clin Oncol. 2021;39(25):2758–2767.
   PubMed Web of Science ®Google Scholar
• Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Hematol. 2019;185(3):492–502.
   PubMed Web of Science ®Google Scholar
• Leypoldt LB, Besemer B, Asemissen AM, et al. Updated interim analysis of the GMMG-CONCEPT trial investigating isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma. HemaSphere. 2021;5(S2):47.
   Google Scholar
• Cruz-Munoz M-E, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297–305.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma. BMS Newsroom. [cited 2020 Jul 06]. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-reports-primaryresults-eloquent-1-study.
   Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45–e54.
   PubMed Web of Science ®Google Scholar
• Derman B, Zonder J, Kansagra A, et al. Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8011.
   Google Scholar
• Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642.
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-Dexamethasone for triple-class refractory multiple Myeloma. N Engl J Med. 2019;381(8):727–738.
   PubMed Web of Science ®Google Scholar
• White DJ, LeBlanc R, Baljevic M, et al. Selinexor, Lenalidomide and Dexamethasone (SRd) for patients with relapsed/refractory and newly diagnosed multiple Myeloma. Blood. 2020;136(Suppl 1):45-46.
   Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Usmani SZ, Mateos MV, et al. Updated phase 1 results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 bispecific antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl 1):27.
   Google Scholar
• Munshi N, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. J Clin Oncol. 2020;38(15_suppl):8503.
   Google Scholar
• Madduri D, Berdeja J, Usmani S, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen directed chimeric antigen receptor T-cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):22-25.
   Web of Science ®Google Scholar
• Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812–2815.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Giri S, Grimshaw A, Bal S, et al. Evaluation of Daratumumab for the treatment of multiple Myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 2020;6(11):1759–1765.
   PubMed Web of Science ®Google Scholar
• Cavo M, Dimopoulos MA, San-Miguel J, et al. Comparative efficacy of Bortezomib, Melphalan, and Prednisone (VMP) with or without Daratumumab versus VMP alone in the treatment of newly diagnosed multiple Myeloma: propensity score matching of ALCYONE and vista phase III studies. Clin Lymphoma Myeloma Leuk. 2020;20(7):480–489.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Usmani SZ, Hulin C, et al. Daratumumab Plus Lenalidomide And Dexamethasone (D-Rd) Versus Lenalidomide And Dexamethasone (Rd) In Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): frailty subgroup analysis of MAIA. Presented at 2nd European Myeloma Network Meeting. 2021;Virtual Abstract BO5.
   Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380.
   PubMed Web of Science ®Google Scholar
• Drent E, Poels R, Mulders MJ, et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS One. 2018;13(5):e0197349.
   PubMed Web of Science ®Google Scholar
• Cook G, Larocca A, Facon T, et al. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia. 2020;34(9):2285–2294.
   PubMed Web of Science ®Google Scholar